CDC finds lower RSV hospitalization rates for infants receiving prevention products
The Centers for Disease Control and Prevention May 8 released an analysis that found declines in hospitalizations for infants infected with respiratory syncytial virus during the 2024-2025 RSV season — the first with widespread availability of the maternal RSV vaccine and nirsevimab, a long-acting monoclonal antibody. Rates were 45% to 52% lower for infants less than 3 months old and 28% to 43% lower for those less than 8 months old. As of February, an estimated 66% of infants received either the maternal RSV vaccine or nirsevimab during the 2024-2025 season.
Related News Articles
Headline
Wrenetha Julion, Ph.D., R.N., of Rush University Medical Center, and Paul Florsheim, Ph.D., of the University of Wisconsin-Milwaukee, discuss the collaborative…
Blog
Even before the COVID pandemic, the mental health and wellness of our young people was failing. The pandemic exacerbated the crisis and made it difficult for…
Headline
Nearly 1 in 10 infants (9.8%) were admitted to a neonatal intensive care unit in 2023, an increase of 13% from 2016, according to a report by the Centers for…
Headline
U.S. births grew 1% in 2024 to 3.6 million, according to preliminary data from the Centers for Disease Control and Prevention. The cesarean delivery rate…
Headline
The National Institutes of Health April 7 released a study that found twins — smaller at birth on average than singletons — develop slower in early pregnancy…
Headline
A case study by the AHA's Community Health Improvement network explains how Children’s Mercy Kansas City created a new model to coordinate its community…